Technical Analysis for VAXX - Vaxxinity, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| F | 0.00 | 0.00% | 0.00 |
Earnings due: Nov 6
*** please verify all earnings dates ***| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 20 DMA Resistance | Bearish | 0.00% | |
| 50 DMA Resistance | Bearish | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Gapped Up | Strength | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| 20 DMA Resistance | Bearish | -50.00% | |
| 50 DMA Resistance | Bearish | -50.00% | |
| Shooting Star Candlestick | Bearish | -50.00% | |
| Wide Bands | Range Expansion | -50.00% | |
| Oversold Stochastic | Weakness | -50.00% |
| Alert | Time |
|---|---|
| Possible NR7 | about 21 hours ago |
| Gap Up Closed | 2 days ago |
| 50 DMA Resistance | 2 days ago |
| 20 DMA Resistance | 2 days ago |
| 10 DMA Resistance | 2 days ago |
Get this analysis on your stocks daily!
- Earnings date: 11/06/2024
Vaxxinity, Inc. Description
Vaxxinity, Inc., a biotechnology company, focuses on developing product candidates for human use in the fields of neurology and coronaviruses in the United States. The company engages in developing UB-311 that targets toxic forms of aggregated amyloid-b in the brain to fight Alzheimer's disease; UB-312 that targets toxic forms of aggregated a-synuclein in the brain to fight Parkinson's disease and other synucleinopathies, such as dementia with Lewy Body and multiple system atrophy; and an anti-tau product candidate for various neurodegenerative conditions, including AD It is also developing UB-313 that targets Calcitonin Gene-Related Peptide to fight migraines; and Anti-PCSK9 that targets proprotein convertase subtilisin/kexin type 9 serine protease to lower low-density lipoprotein cholesterol and reduce the risk of cardiac events, as well as UB-612/UB-612A for Covid-19 prevention. The company has a collaboration with United Biomedical, Inc. for the development of UB-612 in Taiwan. Vaxxinity, Inc. was founded in 2014 and is based in Dallas, Texas.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Alzheimer's Disease Parkinson's Disease Neurological Disorders Dementia Amyloidosis Neurodegenerative Disorders Lewy Body Dementia Migraine Multiple System Atrophy Neuropathology Pcsk9
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 2.45 |
| 52 Week Low | 0.0001 |
| Average Volume | 12,614 |
| 200-Day Moving Average | 0.48 |
| 50-Day Moving Average | 0.04 |
| 20-Day Moving Average | 0.03 |
| 10-Day Moving Average | 0.01 |
| Average True Range | 0.07 |
| RSI (14) | 45.05 |
| ADX | 18.45 |
| +DI | 5.85 |
| -DI | 8.30 |
| Chandelier Exit (Long, 3 ATRs) | -0.12 |
| Chandelier Exit (Short, 3 ATRs) | 0.22 |
| Upper Bollinger Bands | 0.08 |
| Lower Bollinger Band | -0.03 |
| Percent B (%b) | 0.29 |
| BandWidth | 446.40 |
| MACD Line | -0.01 |
| MACD Signal Line | -0.01 |
| MACD Histogram | -0.0015 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 0.09 | ||||
| Resistance 3 (R3) | 0.10 | 0.08 | 0.07 | ||
| Resistance 2 (R2) | 0.08 | 0.06 | 0.07 | 0.07 | |
| Resistance 1 (R1) | 0.04 | 0.04 | 0.03 | 0.03 | 0.06 |
| Pivot Point | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 |
| Support 1 (S1) | -0.02 | 0.00 | -0.03 | -0.03 | -0.06 |
| Support 2 (S2) | -0.04 | -0.01 | -0.04 | -0.07 | |
| Support 3 (S3) | -0.08 | -0.04 | -0.07 | ||
| Support 4 (S4) | -0.09 |
